NasdaqCM - Delayed Quote • USD
Compugen Ltd. (CGEN)
At close: 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -0.02 | -0.08 | 0 | -0.29 |
| Low Estimate | -0.11 | -0.11 | -0.17 | -0.45 |
| High Estimate | 0.07 | -0.05 | 0.26 | -0.09 |
| Year Ago EPS | -0.11 | -0.11 | -0.21 | 0 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 1 | 3 | 3 |
| Avg. Estimate | 6.21M | 2.42M | 38.6M | 23.52M |
| Low Estimate | 2.42M | 2.42M | 35.8M | -- |
| High Estimate | 10M | 2.42M | 40M | 50M |
| Year Ago Sales | -- | -- | 33.46M | 38.6M |
| Sales Growth (year/est) | -- | -- | 15.40% | -39.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.12 | -0.12 | -0.09 | 0.22 |
| EPS Actual | -0.11 | -0.11 | -0.11 | 0.11 |
| Difference | 0.01 | 0.01 | -0.02 | -0.11 |
| Surprise % | 8.30% | 8.30% | -22.20% | -50.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.02 | -0.08 | 0 | -0.29 |
| 7 Days Ago | -0.02 | -0.08 | 0 | -0.29 |
| 30 Days Ago | -0.02 | -0.08 | 0 | -0.29 |
| 60 Days Ago | 0.07 | -0.05 | -0.04 | -0.33 |
| 90 Days Ago | -0.12 | -0.12 | -0.33 | -0.32 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CGEN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 81.80% | -- | -- | 1.60% |
| Next Qtr. | 27.30% | -- | -- | 10.50% |
| Current Year | 100.00% | -- | -- | 5.20% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Truist Securities: Buy to Buy | 3/8/2024 |
| Maintains | Stifel: Buy to Buy | 12/19/2023 |
| Reiterates | Truist Securities: Buy to Buy | 8/23/2023 |
| Reiterates | EF Hutton: Buy to Buy | 8/7/2023 |
| Reiterates | EF Hutton: Buy | 6/6/2023 |
| Reiterates | EF Hutton: Buy to Buy | 5/26/2023 |
Related Tickers
EVGN Evogene Ltd.
0.6120
-4.37%
ENLV Enlivex Therapeutics Ltd.
1.3200
-5.71%
PSTX Poseida Therapeutics, Inc.
2.0200
+1.00%
PLUR Pluri Inc.
5.25
+3.96%
CGEM Cullinan Therapeutics, Inc.
15.66
-13.29%
XTLB XTL Biopharmaceuticals Ltd.
2.4400
0.00%
BLRX BioLineRx Ltd.
0.6565
+2.56%
APLT Applied Therapeutics, Inc.
4.3800
-7.59%
ACIU AC Immune SA
2.3600
-0.84%
FGEN FibroGen, Inc.
1.1500
-1.71%